Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Drug Manufacturers - Specialty & Generic

Healthcare
$4.78 +0.14%

+$0.01 today

Market cap
$791.33M
Beta
0.24
P/E (TTM)
5.6
EPS (TTM)
$0.63
52W Low $0.66High $5.78

Volume 2.22M

Average 2.35M

IRWD Other Investing Activities

Investing cash flows not reported separately.

Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD

Other Investing Activities · Q1 FY2026 · quarter ended Mar 2026

Other investing activities outflow grows to $0

Q1 FY2026 other investing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other investing activities was $4K.

Context

  • Other investing activities amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Other investing activities increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other investing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$4K— YoY
Other Investing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Investing Activities history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Other Investing Activities vs competitors

How IRWD compares with its peers on the latest reported figures

  • IRWD's LTM Mar 2026 other investing activities of $4K is the 2nd largest of the 3 companies compared; the peer median is $35M.
  • Other investing activities amounts to 0.0% of revenue for IRWD, versus a peer median of 38.7%.
IRWD Competitors Peer median
Other Investing Activities for IRWD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$70M +900.0%—77.4%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$4K ——0.0%
ARDXArdelyx, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding IRWD) $35M+900.0%—38.7%

Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income528.45M175.07M(1B)880K24.02M
Depreciation & Amortization1.5M1.42M1.58M2.01M1.88M
Deferred Income Tax(333.29M)65.74M72.64M68.09M40.8M
Stock-Based Compensation22.28M27.05M32.01M29.85M17.25M
Change in Working Capital17.73M2.82M11.28M739K39.65M
Accounts Receivables7.71M7.99M924K47.24M35.15M
Inventory00000
Accounts Payables(2.64M)(8.12M)12.38M(20.21M)6.2M
Other Working Capital12.66M2.94M(2.03M)(26.29M)(1.7M)
Other Non-Cash Items25.23M1.67M1.07B1.98M3.45M
Operating Cash Flow261.9M273.76M183.43M103.55M127.04M
Capital Expenditures(265K)(136K)(273K)(142K)(34K)
Acquisitions (Net)00(1.03B)00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(265K)(136K)(1.03B)(142K)(34K)
Debt Repayment0(120.7M)300M(115M)0
Common Stock Issued19.58M9.54M6.36M11.01M216K
Common Stock Repurchased(24.13M)(126.39M)000
Dividends Paid00000
Other Financing Activities19.58M9.54M(29.2M)(2.98M)0
Financing Cash Flow(4.55M)(237.55M)277.16M(106.97M)216K
Effect of Forex Changes00(53K)(32K)(329K)
Net Change in Cash257.08M36.07M(565.78M)(3.6M)126.9M
Free Cash Flow261.63M273.63M183.15M103.41M127.01M

Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Intrinsic Alpha fair value

Locked

Current Price

$4.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.